Results 101 to 110 of about 6,976 (185)

Impact of antiemetic prophylaxis on reducing trastuzumab deruxtecan dose modifications in HER2+/HER2-low breast cancer. [PDF]

Future Oncol
Shin J, Kim JY, Ahn HK, Ahn JS, Park YH.
europepmc   +1 more source

Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression. [PDF]

Einstein (Sao Paulo)
Amarger CD, Rabello MIS, Skaf SC, Moura F, Cassoli JPB, Taranto P, Serrano Usón Junior PL, Kaliks R, Beal JR.   +8 more
europepmc   +1 more source

TUXEDO-4: phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases [PDF]

Maximilian Marhold, Marta Vaz Batista, Isabel Blancas, Cristina Morales, Cristina Saura-Manich, Cristina Saavedra, Manuel Ruíz‐Borrego, Patricia Cortez, Felipe Slebe, Marta Campolier, Juliana C. Santos, José A. Guerrero-Martínez, Carlos Jiménez‐Cortegana, Beate Rottenmanner, Heidrun Forstner, Rupert Bartsch, Matthias Preusser   +16 more
openalex   +1 more source

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2–positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).

, 2022
Kensei Yamaguchi, Yung‐Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min‐Hee Ryu, Daisuke Sakai, Hyun Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee, Kaku Saito, Yoshinori Kawaguchi, Takahiro Kamio, Akihito Kojima, Masahiro Sugihara, Kohei Shitara   +15 more
openalex   +2 more sources

Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies. [PDF]

Oncologist
Park YH, Cortes J, Modi S, Hurvitz SA, Bianchini G, Iwata H, Shitara K, Siena S, Goto Y, Ku GY, Powell CA, Swain SM, Arunachalam M, Janek M, Cheng Y, Chu C, Verma P, Kuptsova-Clarkson N, Mathias E, Goodman E, Rugo HS.   +20 more
europepmc   +1 more source

343MO Unraveling the mechanisms of action and resistance to trastuzumab deruxtecan (T-DXd): Supplementary biomarker analyses from DAISY trial [PDF]

M.F. Mosele, Amélie Lusque, Véronique Dièras, Élise Deluche, Agnès Ducoulombier, Barbara Pistilli, T. Bachelot, F. Viret, C. Lévy, Y.C. Pradat, Nicolas Signolle, Loïc Le Bescond, D. Tran, Nathalie Droin, Michihiko Kobayashi, T. Kakewaga, Marc Deloger, Marta Jimenez, M. Lacroix-Triki, Fabrice André   +19 more
openalex   +1 more source

Trastuzumab deruxtecan in HER2-positive advanced colorectal cancer: a plain language summary of the DESTINY-CRC02 study. [PDF]

Future Oncol
Raghav K.
europepmc   +1 more source

Mechanisms of resistance to trastuzumab deruxtecan in breast cancer elucidated by multi-omic molecular profiling. [PDF]

NPJ Breast Cancer
Sledge GW, Xiu J, Mahtani RL, Sandoval Leon AC, Meric-Bernstam F, Ribeiro JR, Kulkarni NN, Rampa DR, Lee J, Ueno NT, Oberley MJ, Radovich M, Spetzler DB.   +12 more
europepmc   +1 more source

Data from Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors

, 2023
Shunji Takahashi, Masato Karayama, Masato Takahashi, Junichiro Watanabe, Hironobu Minami, Noboru Yamamoto, Ichiro Kinoshita, Chia‐Chi Lin, Young‐Hyuck Im, Issei Achiwa, Emi Kamiyama, Yasuyuki Okuda, Caleb Lee, Yung‐Jue Bang   +13 more
openalex   +1 more source

Complete response following trastuzumab-deruxtecan in a man with HER2-overexpressing metastatic, poorly differentiated scrotal carcinoma. [PDF]

Oncologist
Hofstad M, Zheng J, Tachibana I, Zhang T.   +3 more
europepmc   +1 more source